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Background
- Atherosclerotic cardiovascular disease remains a 
leading cause of death worldwide. 
- Per 2019 ACC/AHA guidelines, statin therapy is 
first-line for primary prevention of ASCVD in 
those with diabetes who are 40-75 years of age. 
- A quick review of patient data in epic identified a 
care gap for patients with diabetes who were not 
compliant with statin recommendations. 
- Our team reviewed patients in this care gap in 
order to identify barriers to statin compliance. 
Aims For Improvement
Aim 1: To understand the root cause(s) for gaps in 
statin therapy within a large ambulatory care 
practice.     
Aime 2: To improve provider awareness of  
indications for statin therapy, as recommended by 
the ACC/AHA guidelines.    
Aim 3: To increase the proportion of patients with 
diabetes at our practice that are on statin therapy.
Intervention
- We identified a care gap of 257 patients with 
diabetes greater than 40 years old within one 
JFMA provider team who were not currently on 
statin therapy as of January 2020. 
- 70 of 257 patients were randomly selected for 
chart review. 
- The team carefully reviewed each of these 70 
charts and identified reasons for non-compliance 
with indication for statin therapy. 
Measurement and Results: Chart Review Next Steps and Lessons Learned
- Our chart review revealed that 50% of 
patients with diabetes who were not on 
statin therapy at JFMA did not have statin 
therapy appropriately addressed by their 
provider.
- Given these findings, we aimed to create an 
EHR Better Practice Advisory (BPA) to 
prompt providers to review this indication 
for statin therapy. 
- This BPA has since been created and 
implemented within our practice. 
- Next steps would include measuring statin 
use after BPA rollout to determine whether 
alerting providers to this statin indication 
improves this care gap. 
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Challenges in the Era of COVID19
- Given the acute nature of the pandemic, 
office priorities and resources were 
concentrated on efforts surrounding 
COVID19. 
- Although barrieres to statin compliance 
were identified and a BPA was made, 
potential next steps such as changes to MA 
rooming process were unable to be explored 
during this time. 
- As ambulatory practice changes in the post-
COVID era, we will need to develop novel 
ways to continue our chronic disease 
management for our vulnerable patients. 
- Barriers such as patient preference, expired 
prescriptions, and failure to address were 
reviewed. 
- Data demonstrated the largest reason for statin 
noncompliace was that it was not addressed by 
provider. 




Statin not addressed within past 2 yrs 32
Statin expired from medication list 12
Discontinued due to age > 75 1
Provider decision 3
Other 3
